Ulcerative proctitis

An update on the pharmacotherapy and management

Krisztina B. Gecse, P. Lakatos

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Ulcerative colitis (UC) presents as proctitis in approximately a quarter of the patients. It may progress into left-sided or extensive colitis in up to 50% of cases upon long-term follow-up.Areas covered: Currently available data on ulcerative proctitis are summarized and critically reviewed. Extensive literature search (MEDLINE) was performed to identify relevant articles up to March 2014.Expert opinion: The short-term goal of the treatment in UC is to induce remission, whereas long-term goals are to maintain remission and prevent disease progression. Topically administered 5-aminosalicylates (5-ASA) and corticosteroids are effective in the treatment of proctitis, although they seem to be underused in everyday practice. Locally administered 5-ASA preparations are more effective than oral compounds. The combination of topical and oral 5-ASA and steroids should be considered for escalation of treatment. Refractory patients should be re-evaluated to exclude for compliance failures, infections or proximal disease extent. True refractory or steroid-dependent patients may require immunomodulators or biological therapy. Alternative medicine can be used complementarily, while experimental approaches are reserved for patients failing conventional medication. Proctocolectomy may be the last resort of treatment. Upon long-term, 5-ASA maintenance treatment is indicated in all UC cases to prevent relapse and disease progression.

Original languageEnglish
Pages (from-to)1565-1573
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number11
DOIs
Publication statusPublished - 2014

Fingerprint

Proctitis
Mesalamine
Drug Therapy
Ulcerative Colitis
Disease Progression
Steroids
Therapeutics
Biological Therapy
Expert Testimony
Immunologic Factors
Colitis
Complementary Therapies
MEDLINE
Compliance
Adrenal Cortex Hormones
Recurrence
Infection

Keywords

  • 5-aminosalicylates
  • Azathioprine
  • Infliximab
  • Steroids
  • Therapy
  • Ulcerative colitis
  • Ulcerative proctitis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Ulcerative proctitis : An update on the pharmacotherapy and management. / Gecse, Krisztina B.; Lakatos, P.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 11, 2014, p. 1565-1573.

Research output: Contribution to journalArticle

@article{d62d2be56761413596901a791a2a29a1,
title = "Ulcerative proctitis: An update on the pharmacotherapy and management",
abstract = "Introduction: Ulcerative colitis (UC) presents as proctitis in approximately a quarter of the patients. It may progress into left-sided or extensive colitis in up to 50{\%} of cases upon long-term follow-up.Areas covered: Currently available data on ulcerative proctitis are summarized and critically reviewed. Extensive literature search (MEDLINE) was performed to identify relevant articles up to March 2014.Expert opinion: The short-term goal of the treatment in UC is to induce remission, whereas long-term goals are to maintain remission and prevent disease progression. Topically administered 5-aminosalicylates (5-ASA) and corticosteroids are effective in the treatment of proctitis, although they seem to be underused in everyday practice. Locally administered 5-ASA preparations are more effective than oral compounds. The combination of topical and oral 5-ASA and steroids should be considered for escalation of treatment. Refractory patients should be re-evaluated to exclude for compliance failures, infections or proximal disease extent. True refractory or steroid-dependent patients may require immunomodulators or biological therapy. Alternative medicine can be used complementarily, while experimental approaches are reserved for patients failing conventional medication. Proctocolectomy may be the last resort of treatment. Upon long-term, 5-ASA maintenance treatment is indicated in all UC cases to prevent relapse and disease progression.",
keywords = "5-aminosalicylates, Azathioprine, Infliximab, Steroids, Therapy, Ulcerative colitis, Ulcerative proctitis",
author = "Gecse, {Krisztina B.} and P. Lakatos",
year = "2014",
doi = "10.1517/14656566.2014.920322",
language = "English",
volume = "15",
pages = "1565--1573",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Ulcerative proctitis

T2 - An update on the pharmacotherapy and management

AU - Gecse, Krisztina B.

AU - Lakatos, P.

PY - 2014

Y1 - 2014

N2 - Introduction: Ulcerative colitis (UC) presents as proctitis in approximately a quarter of the patients. It may progress into left-sided or extensive colitis in up to 50% of cases upon long-term follow-up.Areas covered: Currently available data on ulcerative proctitis are summarized and critically reviewed. Extensive literature search (MEDLINE) was performed to identify relevant articles up to March 2014.Expert opinion: The short-term goal of the treatment in UC is to induce remission, whereas long-term goals are to maintain remission and prevent disease progression. Topically administered 5-aminosalicylates (5-ASA) and corticosteroids are effective in the treatment of proctitis, although they seem to be underused in everyday practice. Locally administered 5-ASA preparations are more effective than oral compounds. The combination of topical and oral 5-ASA and steroids should be considered for escalation of treatment. Refractory patients should be re-evaluated to exclude for compliance failures, infections or proximal disease extent. True refractory or steroid-dependent patients may require immunomodulators or biological therapy. Alternative medicine can be used complementarily, while experimental approaches are reserved for patients failing conventional medication. Proctocolectomy may be the last resort of treatment. Upon long-term, 5-ASA maintenance treatment is indicated in all UC cases to prevent relapse and disease progression.

AB - Introduction: Ulcerative colitis (UC) presents as proctitis in approximately a quarter of the patients. It may progress into left-sided or extensive colitis in up to 50% of cases upon long-term follow-up.Areas covered: Currently available data on ulcerative proctitis are summarized and critically reviewed. Extensive literature search (MEDLINE) was performed to identify relevant articles up to March 2014.Expert opinion: The short-term goal of the treatment in UC is to induce remission, whereas long-term goals are to maintain remission and prevent disease progression. Topically administered 5-aminosalicylates (5-ASA) and corticosteroids are effective in the treatment of proctitis, although they seem to be underused in everyday practice. Locally administered 5-ASA preparations are more effective than oral compounds. The combination of topical and oral 5-ASA and steroids should be considered for escalation of treatment. Refractory patients should be re-evaluated to exclude for compliance failures, infections or proximal disease extent. True refractory or steroid-dependent patients may require immunomodulators or biological therapy. Alternative medicine can be used complementarily, while experimental approaches are reserved for patients failing conventional medication. Proctocolectomy may be the last resort of treatment. Upon long-term, 5-ASA maintenance treatment is indicated in all UC cases to prevent relapse and disease progression.

KW - 5-aminosalicylates

KW - Azathioprine

KW - Infliximab

KW - Steroids

KW - Therapy

KW - Ulcerative colitis

KW - Ulcerative proctitis

UR - http://www.scopus.com/inward/record.url?scp=84904152957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904152957&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.920322

DO - 10.1517/14656566.2014.920322

M3 - Article

VL - 15

SP - 1565

EP - 1573

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 11

ER -